

1 **Coronavirus and Post-COVID-19 Syndrome: A Systematic Review**

2 Sarvinoz Albalushi*¹, Azmaeen Zarif*^{†,2,3}, Suheyla Karaduman⁴, Alesia Talpeka^{5,6}, Khoa Tran⁷

3

4 ¹ University of Debrecan, Debrecen, Egyetem tér 1, 4032 Hungary

5 ² University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Hills Road, Cambridge,
6 Cambridgeshire, CB2 0SP, United Kingdom

7 ³ Gonville & Caius College, University of Cambridge, Trinity Street, Cambridge, Cambridgeshire, CB2 1TA,
8 United Kingdom

9 ⁴ Uludag University Medical School, Özlüce, Uludağ Üniv., 16285 Nilüfer/Bursa, Türkiye

10 ⁵ Belarusian State Medical University, Prospekt Dzerzhinskogo 83, Minsk 220116, Belarus

11 ⁶ Minsk City Clinical Oncology Center, 1st City Clinical Hospital, Nezavisimosti Svenue, 64, Minsk 220040

12 ⁷ Pham Ngoc Thach University of Medicine, 2 Đ. Dương Quang Trung, Phường 12, Quận 10, Thành phố Hồ
13 Chí Minh, Vietnam

14

15 [†] Corresponding author:

16 Azmaeen Zarif

17 Gonville & Caius College

18 University of Cambridge

19 Trinity Street

20 Cambridge

21 Cambridgeshire

22 CB2 1TA

23 United Kingdom

24 Email: az397@cam.ac.uk

25

26 **Abstract**

27

28 Coronavirus infectious Disease 2019 (COVID-19) was first reported in Wuhan, China, and with its
29 rapidly mutating variants, it soon became a global concern. In response to the pandemic, intensive
30 research and development efforts led to the development of six vaccines approved by the World Health
31 Organization (WHO). Coronavirus is divided into four genera: alpha, beta, gamma and delta. Its unstable
32 ssRNA resulted in multiple strains in a short period, which acted as a selection pressure for
33 transmissibility. Sequelae of COVID-19 infection include multiple syndromes which have been reported
34 at high incidence globally. Using the Cochrane guidelines and the Preferred Reporting Items for
35 Systematic Reviews and Meta-Analyses (PRISMA), we present a systematic review of the most common
36 syndromes reported. A total of 12 eligible studies were included in this review. Syndromes reported in the
37 literature include immune thrombocytopenic purpura (ITP), viral encephalomyelitis, hemophagocytic
38 lymphohistiocytosis, thrombotic thrombocytopenic purpura (TTP), Guillain-Barrè syndrome (GBS) and
39 postural orthostatic tachycardia syndrome (POTS). We cover the hypothesized pathophysiology,
40 presenting symptoms and treatment for each respective syndrome. We aim to discuss coronavirus and its
41 variants to provide a foundation on which to examine the syndromes manifested after COVID-19
42 infection (post-COVID-19 syndrome).

43

44 **Keywords:** COVID-19, Guillain-Barrè Syndrome, Hemophagocytic Lymphohistiocytosis, Immune
45 Thrombocytopenic Purpura, Postural Orthostatic Tachycardia Syndrome, single stranded ribonucleic acid,
46 Thrombotic Thrombocytopenic Purpura

47

48

49

50

51

52 **Introduction**

53

54 *Background*

55 The first cases of Coronavirus infectious Disease 2019 (COVID-19), an infectious disease caused by the
56 SARS-CoV-2 virus, were reported in Wuhan, China in late December 2019 (Li et al., 2020; Roy, Roy &
57 Paul, 2020). The first four cases were reported as respiratory illnesses and initially referred to as
58 ‘pneumonia of unknown etiology’, which later emerged as the global COVID-19 pandemic (Tan et al.,
59 2020). Since its emergence, several variants have emerged. Despite strict preventive measures (sanitizing
60 probable fomites, wearing face masks, regular hand washing, promoting personal hygiene, and using
61 alcohol-based hand sanitizers) recommended by the Centers for Disease Prevention and Cure (CDC) and
62 World Health Organisation (WHO), the number of affected individuals till date has reached 695 million
63 where 6.9 million individuals died and 667 million recovered (Worldometer. (n.d.)).

64

65 In response to the pandemic, groundbreaking efforts were made by scientists in collaboration with
66 pharmaceutical companies to develop six COVID-19 vaccines approved by the WHO’s Strategic
67 Advisory Group of Experts on Immunization (SAGE). These vaccines included BNT162b2 mRNA
68 (Pfizer), mRNA-1273 (Moderna), and Janssen Ad26.CoV2.S (Johnson & Johnson), AZD1222
69 (Oxford/AstraZeneca), CoronaVac (Sinovac Biotech), and BBIBP-CorV (Sinopharm). According to the
70 WHO, by March 2022, 90% of the global population had antibodies against COVID-19 disease either
71 through infection or through vaccination (WHO, 2022a). Alongside the development and mass
72 administration of vaccines, several mutants of SARS-CoV-2 have been identified across the globe, which
73 resulted in subsequent infection cycles and an exponential expansion in the geographical range of the
74 disease.

75

76 Coronaviruses are a group of single-stranded RNA (ssRNA) viruses that fall under the family
77 Coronaviridae, subfamily Coronavirinae, and order Nidovirales. These viruses transmit infection from

78 human to human and also infect birds (Yousefi & Eslami, 2022). These viruses were documented almost
79 50 years ago and over these five decades, different viruses from this family have been identified in
80 different areas of the globe. The viruses can be divided into four different genera: *Alpha coronavirus* (also
81 known as human coronaviruses, HCoV), *Beta coronavirus* (this category includes Middle Eastern
82 Respiratory syndrome-related coronavirus, MERS-CoV, and the widely-known SARS-CoV), *Gamma*
83 *coronavirus*, and *Delta coronavirus*. The viruses from the last two genera mostly infect birds (Nakagawa,
84 Lokugamage, & Makino, 2016). Based on the similarity of a sequence of nucleic acid, the newly
85 identified Severe acute respiratory syndrome, coronavirus 2 (SARS-CoV-2) can be categorized as beta
86 coronavirus (Xiao et al., 2020).

87

88

89 *Variants of Coronavirus*

90 SARS-CoV-2 is an RNA virus with an unstable genome. This poses a constant threat of developing
91 mutant strains that may become dominant through natural selection, often with higher transmissibility
92 than previous strains.

93

94 Throughout the pandemic, several variants of SARS-CoV-2 have emerged. These mutations can be
95 caused by environmental mutagens such as metal ions and UV radiation, as well as endogenous
96 components of the virus (Sanjuán & Domingo-Calap, 2016). Typically, RNA viruses evolve gradually
97 over time (Morley & Turner, 2017). During the pandemic, the WHO collaborated with national and
98 international researchers to monitor the changes in the patterns of transmission of SARS-CoV-2, its
99 clinical presentation, severity, and impact on public health measures. The WHO established close
100 monitoring networks to identify potential Variants of Interest (VOIs) and Variants of Concern (VOCs)
101 and to assess their risk to public health (WHO, 2022b). To date, four VOCs have been identified: Alpha,
102 Beta, Gamma, and Delta.

103

104 The Beta variant (B.1.351) was first identified in South Africa in May 2020. This variant has been found
105 to affect younger people more severely than previous strains. Since its initial detection, it has been
106 identified in 80 countries and was thought to be the main cause of the third wave of the pandemic in
107 South Africa. Of particular concern is the E484K mutation found in this variant, which allows it to evade
108 the immune system more easily (CDC, 2020).

109
110 The U.K. was the first location where the Alpha variant (B.1.1.7) was identified., and it was the prime
111 cause of the third wave in the U.K. This strain is not only highly transmissible but it is extremely lethal. It
112 is 30-70% more transmissible and lethal than the original strain (Raheem et al., 2021). Note that these
113 strains do not result from a single mutation but rather are the result of, to date, 149 mutations that have
114 been identified in more than a hundred sequenced strains since the beginning of the pandemic till May
115 2020 (Awadasseid et al., 2021). These mutations usually change the spike proteins of the virus. These
116 spike proteins are used by the virus to enter the cells in humans using the angiotensin-converting enzyme
117 2 (ACE2) receptor (Casalino et al., 2020). The first notable strain of the novel coronavirus, which became
118 a predomination globally, was the D614G variant, also known as G614. This variant was the result of a
119 missense mutation (23403A>G) of the S1 subunit (spike protein component). This mutation changed the
120 original strain (D614) that was identified in Wuhan. It was originally spotted in Europe and, within a
121 month, dominated the globe. The G614 variant had higher transmissibility than the original Wuhan
122 variant or any other variant (Korber et al., 2020). In addition to having a higher transmissibility, it was
123 also found to enhance the risk of death among individuals (Challen et al., 2021; Davies et al., 2020).

124
125 The Gamma variant (P.1) was first identified in Brazil in November 2020. It is twice as transmissible as
126 the previous strain and was the primary cause of the second deadly wave of the coronavirus. Studies have
127 shown that existing vaccines provide only 54-79% protection against this variant (WHO, 2022c).

128

129 The Delta variant (B.1.617.2) was first reported by the WHO on June 21, 2021. It is highly contagious
130 and, to date, the fastest-spreading strain. This variant targets vulnerable populations, especially in areas
131 with low COVID-19 vaccination rates. It was first identified in India, where it was 60% more
132 transmissible than other strains and posed a higher risk of reinfection (Cherian et al., 2021). The Delta
133 variant drove the second deadly wave of Coronavirus in India in the summer of 2021, affecting vulnerable
134 individuals with pre-existing conditions (Mallapaty et al., 2021). It spread to 92 countries, accounting for
135 20% of new cases in the US and 60% of new infections in the UK (Mishra et al., 2021). A mutation in the
136 spike protein of the Delta virus has led to a new variant known as Delta plus, which has been found in
137 several countries, including Nepal, Portugal, the US, the UK, and Russia (Kupferschmidt & Wadman,
138 2021).

139
140 The Omicron variant (B.1.1.529) was first reported by WHO on November 24, 2021, and just two days
141 later it was declared a variant of concern due to its increased detection in the South African region and the
142 identification of several mutations in the spike protein, particularly in the immunogenic region (WHO,
143 2021). This variant has nearly 32 mutations in the spike protein and 10 mutations in the receptor-binding
144 domain. It was first identified in the U.S. and has since spread rapidly throughout the world. The
145 mutations in the spike protein have made it easier for the virus to infect human cells and evade the
146 immune response, making it more transmissible than previous strains. The most notable mutations are
147 N501Y, D614G, and E484K, which allow the virus to escape the protection offered by currently available
148 vaccines. These structural changes also distort the antibody binding sites, further compromising the
149 immune response to the infection (Kamble et al., 2022).

150

151 *Composition and Genome Structure of Coronavirus*

152 The family Coronaviridae encompasses the Coronavirus, which is further divided into two subfamilies:
153 Coronavirinae and Torovirinae. ssRNA and +ssRNA are about 26–32 kb in genome size. Coronaviruses
154 are typically classified into four genera based on their genomic structure and host range. The four genera

155 of Coronaviridae are Alpha, Beta, Gamma, and Delta Coronavirus. The Alpha and Beta genera primarily
156 infect mammals, while the Gamma and Delta genera primarily infect birds. Bats are the natural reservoir
157 of Coronaviruses, and they are mainly responsible for the spread of novel coronavirus (Li et al., 2019).
158 Coronavirus has at least 27 proteins including four structural proteins, 15 non-structural proteins, and 8
159 auxiliary proteins. Its envelope includes four spike-shaped proteins including envelope proteins (E),
160 glycoproteins (S), nucleocapsid (N), and membrane proteins (M). These proteins play a vital role in
161 binding to the host cell and facilitating entry of the virus. Sixteen non-structural proteins (nsp1–16)
162 constitute a viral transcriptase-replicase complex that is encoded by two polypeptides (pp1a and pp1ab).
163 These non-structural proteins are primarily involved in the formation of double-membraned vesicles that
164 are derived from the rough endoplasmic reticulum, which plays a crucial role in the replication and
165 transcription of the virus, serving as the primary site for these processes.

166

167 To reduce the number of mutations in the RNA genome, Coronavirus also encodes exoribonuclease
168 (EXoN) which is produced by the nsp14 protein. The spike protein is a key factor in the virus's ability to
169 enter host cells, with the receptor-binding domain (RBD) located in the S1 subunit responsible for
170 binding to the host cell receptor and the S2 subunit facilitating fusion of the viral and host cell membranes
171 (Chen, Liu & Guo, 2020).

172

173 Spike glycoprotein (S), a structural protein that is located on the outer envelope of the virus, attaches to
174 the host-receptor angiotensin-converting enzyme 2 (ACE2). The S protein of Coronavirus contains
175 carboxyl (C)-terminal S2 subunit and amino (N)-terminal S1 subunit with a length ranging from 1104 to
176 1273 amino acids. The S1 subunit is the receptor-binding domain (RBD) which has an external
177 subdomain and a core subdomain. These two subunits span around 200 residues. The core subdomain of
178 RBD is primarily responsible for the formation of S trimer particles. The two exposed loops on the
179 surface of the external subdomain are responsible for binding with ACE2.

180

181 Infection with COVID-19 has resulted in many different post-infective syndromes being reported, termed
182 post-COVID syndrome. We attempted to systematically synthesize all the evidence available on sequelae
183 syndromes post-COVID-19 infection.

184

185 **Method**

186 The guidelines of the Cochrane Handbook for a systematic review and the Preferred Reporting Items for
187 Systematic Reviews and Meta-Analyses (PRISMA) (Vrabel, 2015) statement were followed to structure
188 this systemic review (Higgins et al. 2019).

189

190 *Search Strategy*

191 A search strategy was established based on key terms for ‘Syndrome’ and ‘COVID-19’. Moreover, MeSH
192 terms were reviewed to add a term to the search strategy.

193

194 PubMed was searched using the search strategy given in Table 1 to ensure all the studies conducted were
195 captured. The search was limited to the last 4 years from 2019 (the emergence of COVID-19) to 2022.

196

197

198

199

200

201

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

202

203

204

205 **Table 1.** Search strategy for the review.

Step	Term	Search term
Step 1	Syndrome	‘Syndromes’ OR ‘Symptom Cluster’ OR ‘Symptom Clusters’
Step 2	COVID-19	(‘COVID’ OR ‘COVID-19’ OR ‘nCoV’ OR ‘coronavirus’ OR ‘Middle East respiratory syndrome’ OR ‘MERS’ OR ‘Severe Acute Respiratory Syndrome’ OR ‘SARS’)

206
207

208 *Screening Process*

209 Searches were downloaded in the form of an Excel sheet. Duplicates were removed from the downloaded
210 searches. Titles and abstracts were screened based on inclusion and exclusion criteria (see below). Then,
211 full-length articles were screened using the same criteria. The PRISMA flowchart summarizes the
212 screening and selection process of the studies (see Supplementary Materials, Figure S1).

213

214 *Determining the eligibility of the studies*

215 Inclusion and exclusion criteria to determine the eligibility of screened studies for inclusion in the review
216 are detailed below.

217

218 Inclusion Criteria:

- 219 • All quantitative studies, case reports, and case series reports on any syndrome that occurred after
220 COVID-19 infection
- 221 • Both males and females from any age group were included

- 222 • Participants must have been diagnosed with COVID-19 infection
- 223 • Non-English studies were included if a full-text article was available in English

224

225 Exclusion Criteria:

- 226 • Qualitative studies, literature reviews, editorials, and policy documents were excluded
- 227 • Studies conducted on patients with any other infection than COVID-19
- 228 • Studies not having the outcome of interest (i.e., post-COVID-19 infection syndrome)
- 229 • No full text of the study was available

230

231 Inclusion and exclusion criteria based on intervention, comparator, population, and outcome of review
232 question are detailed in the Supplementary Materials (Table S1).

233

234 *Risk of Bias*

235 The risk of bias in studies was assessed using the Joanna Briggs Inventory (JBI) for case reports (see
236 Supplementary Materials, Table S2) as case reports were the predominant type of manuscript expected for
237 the given review question. JBI for case reports assesses the risk of bias in included studies using eight
238 questions. These questions assess if: the patient's demographics are clearly defined; there is an adequate
239 description of the patient's history; the current condition is described comprehensively; results of
240 diagnostic tests and assessment methods are mentioned clearly; there is a clear description of treatment or
241 intervention procedures; there is a comprehensive assessment of post-intervention clinical condition; and
242 unanticipated or adverse events are adequately reported. Each question is answered in terms of yes, no,
243 unclear, and not applicable (Munn et al., 2020).

244

245 *Data Extraction*

246 After screening, manuscript data were extracted. Extracted data (see Table 2) included: author, year of
247 publication, sample characteristics (including sample size, gender percentage of sample, mean age of the
248 sample, or any other sample-specific characteristics), study design, study characteristics (outcome of the
249 study), and results.

250

251 Table 2: Data Extraction table

Author, Year	Country	Study Design	Sample characteristics	Syndrome reported	Significant findings
Revuz et al., 2020	France	Case series	57-year-old woman; 76-year-old man; 39-year-old man	Immune Thrombocytopenic Purpura (ITP)	Severity of haemorrhagic syndrome not correlated with the severity of COVID-19 infection. Intravenous immunoglobulins(1g/kg) constituted best treatment for the syndrome.
Bennett et al., 2020	USA	Case report	73-year-old woman	Immune Thrombocytopenic Purpura (ITP)	The blood count of the patient was remarkable for leukopenia and severe thrombocytopenia. Platelets count of patients was <3k/ μ L. Patient was suspected of ITP and responded to treatment of Intravenous immunoglobulins.

Author, Year	Country	Study Design	Sample characteristics	Syndrome reported	Significant findings
Ofluoglu et al., 2020	Turkey	Case report	48-year-old male	Viral encephalomyelitis	Acute lesions were found in the brain and upper cervical cord on MRI. Patient was treated with Hydroxychloroquine, Favipiravir, Levetiracetam, and acyclovir.
Nicolotti et al., 2021	Italy	Case report	44-year-old woman	Thrombotic thrombocytopenic purpura (TTP)	Patient was presented with acute kidney injury, severe anemia, and respiratory failure due to COVID-19. Diagnostic tests confirmed TTP and patient was treated with plasma exchange therapy for 7 days and methylprednisolone therapy for 5 days.
Dhingra et al., 2021	India	Case report	35-year-old woman	Thrombotic thrombocytopenic purpura (TTP)	Blood examination of patient indicated thrombocytopenia (Platelets 20k/ μ L), anemia (Hb-8.25) and signs of 8% schistocytes and hemolysis. Treatment included plasma exchange therapy and cryo poor plasma as a replacement fluid.

Author, Year	Country	Study Design	Sample characteristics	Syndrome reported	Significant findings
Naous et al., 2021	Lebanon	Case report	69-year-old woman	Hemophagocytic lymphohistiocytosis	Patient was presented with hyperosmolar state and high inflammatory marker. Hemophagocytosis was shown in bone marrow aspirate smear review. Patient died in spite of appropriate treatment.
Kalita et al., 2021	India	Case series	40-year-old woman; 2-year-old man	Hemophagocytic lymphohistiocytosis	Patient 1 was presented with bilateral crepitations and rhonchi. Treatment of patient included antibiotics, oxygen support, intravenous steroids, and heparin. Patient 2 was presented with feeding intolerance and abnormal body movements. Bone marrow smears were suggestive of hemophagocytic lymphohistiocytosis. The patient was treated with antibiotics, steroids, fluconazole, and anti-epileptic.

Author, Year	Country	Study Design	Sample characteristics	Syndrome reported	Significant findings
Tholin et al., 2020	Norway	Case report	70-year-old man	Hemophagocytic lymphohistiocytosis	Patient was admitted to the hospital with complaints of diarrhea, fever, and abdominal pain. His health deteriorated with time with marked rise in CRP, ferritin, and thrombocytopenia. His interleukin-6 receptor level was elevated indicating immune activation and bone marrow biopsy smear demonstrated hemophagocytosis. Patient was treated with tocilizumab 800 mg intravenously, infusion of chimeric antigen receptor T cells.
Blitshteyn & Whitelaw, 2021	USA	Case series	Twenty patients (70% female)	Autonomic disorders	Out of 20 patients, 15 had postural orthostatic tachycardia (POTS), 2 had orthostatic hypotension, and 3 had neurocardiogenic syncope. Even after 8 months patients had residual autonomic symptoms.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Author, Year	Country	Study Design	Sample characteristics	Syndrome reported	Significant findings
Johansson et al., 2021	Sweden	Case series	42-year-old woman; 28-year-old woman; 37-year-old man	Postural orthostatic tachycardia syndrome	Patient 1 had palpitations, dizziness exercise intolerance. Non- pharmacological treatment included intake, avoidance of orthostatic trig; and compression stockings. Patient presented with symptoms of lightheadedness, chest pain, dyspnea, headache. POTS was confirmed by up tilt and active standing. Patient 3 presented with fever, sore throat, muscle weakness, fatigue, and palpitations. Patient received pyridostigmine 10 mg ×3 and propranolol 10 mg ×3 times day.

Author, Year	Country	Study Design	Sample characteristics	Syndrome reported	Significant findings
Alberti et al., 2020	Italy	Case report	71-year-old male	Guillain-Barrè syndrome	Patient was presented with subacute onset of paresthesia with rapidly evolving flaccid tetraparesis. Biological markers were interpreted as acute polyradiculoneuritis and diagnosis of Guillain-Barrè syndrome (GBS). Patient was treated with immunoglobulins (0.4g/kg/d), hydroxychloroquine and antiviral therapy. Patient died 24 hours after the admission to the hospital.
Sedaghal & Karimi, 2020	Iran	Case report	65-years-old male	Guillain-Barrè syndrome	Patient was presented with acute progressive symmetric ascending quadriparesis. Electrodiagnostic test confirmed the diagnosis of GBS. Patient was treated with IV immunoglobulin (0.4g/kg/d for 5 days).

252
253

254 **Results**

255

256 *Characteristics of the study and sample*

257 Twelve studies (three case series, eight case reports, and one retrospective cohort study) based on the
258 inclusion criteria were included in the review. The studies that met the inclusion criteria were from
259 different regions around the globe. Six studies were from European regions: France (Revuz et al., 2020),
260 Turkey (Otluglu et al., 2020), Norway (Tholin et al., 2020), Sweden (Johansson et al., 2021), and two
261 from Italy (Nicolotti et al., 2021; Alberti et al., 2020). Two studies were from North America (Bennett et
262 al., 2020; Blitshteyn & Whitelaw, 2021), four from Asia: two from India (Dhingra et al., 2021; Kalita et
263 al., 2021), and one each from Lebanon (Naous et al., 2021) and Iran (Sedaghal & Karimi, 2020). A total
264 of 36 patients constitute the sample size of the review. The age of the patients ranged from 28 years to 76
265 years, however, one study reported the case of a 2-year-old child experiencing post-COVID-19 syndrome
266 (Kalita et al., 2021).

267

268 *Syndromes*

269 All the included studies reported syndromes experienced by the patients after COVID-19 infection. The
270 syndromes reported in the literature include immune thrombocytopenic purpura (ITP), viral
271 encephalomyelitis, thrombotic thrombocytopenic purpura (TTP), hemophagocytic lymphohistiocytosis,
272 postural orthostatic tachycardia syndrome (POTS), and Guillain-Barré syndrome (GBS). Two case reports
273 were on ITP (Revuz et al., 2020; Bennett et al., 2020). ITP diagnosis was determined based on reduced
274 platelet counts, an increased ferritin level, and thrombocytopenia, as indicated in bloodwork. In both case
275 reports of ITP, intravenous immunoglobulin (IVIG; 1 g/kg) constituted the first line of treatment and
276 patients responded well to the treatment. One of the included case studies was based on viral
277 encephalomyelitis experienced by patients after COVID-19 infection. Diagnosis was based on
278 hyperintense lesions, found on MRI, on the surface of the temporal lobe and posterior medial cortex. Two
279 cases of TTP were reported where the diagnosis was established based on: anemia, thrombocytopenia,

280 reduced activity of ADAMTS13 and increased activity of anti-ADAMTS13 antibodies. Plasma exchange
281 therapy was performed for both patients. One patient was given a fresh plasma transfusion followed by a
282 five-day course of methylprednisolone (Nicolotti et al., 2021) while the other patient received cryo-poor
283 plasma and received two doses of IM Vincristine and one dose of IM Rituximab (Dhingra et al., 2021).
284 Both patients recovered and were discharged. Three of the included case reports presented the case of
285 hemophagocytic lymphohistiocytosis (Tholin et al., 2020; Kalita et al., 2021; Naous et al., 2021). The
286 diagnosis was made based on bone marrow smears in all cases. The patients were treated with steroids,
287 antibiotics, and fluids. One patient was also infused with chimeric antigen receptor T-cells (Tholin et al.,
288 2020). One of the patients did not survive despite high-dose steroid therapy and antibiotics (Naous et al.,
289 2021). Other syndromes identified in the literature included POTS (Blitshteyn & Whitelaw, 2021;
290 Johansson et al., 2021) and GBS (Alberti et al., 2020; Sedaghal & Karimi, 2020). For POTS, the
291 diagnosis was confirmed using a head-up tilt test and measuring heart rate during active standing.
292 Acetylcholinesterase inhibitors and beta blockers were for the pharmacological treatment of POTS in
293 addition to non-pharmacological treatments such as abdominal binders, waist-high compression
294 stockings, and fluids. For GBS, the diagnosis was based on biological markers suggestive of
295 polyradiculoneuritis. IVIG constituted the first line of treatment. The details of each of the syndromes are
296 presented as follows.

297

298 *Immune Thrombocytopenic Purpura*

299 ITP is a bleeding disorder that is distinguished by a reduced number of platelets in the blood, known as
300 isolated thrombocytopenia, where the platelet count is less than $150\text{k}/\mu\text{L}$. It is a rare disease with a
301 prevalence of 20 individuals per 1 million adults, typically affecting adults over the age of 50 (Michel,
302 2009). Pregnant women and those of childbearing age are also at increased (Provan & Newland, 2015).
303 The disease course is generally more favourable in children than in adults. Children tend to achieve full
304 remission sooner than adults, who often have a more chronic disease picture. Nonetheless, adults can

305 experience spontaneous remission, which typically occurs during the initial months of diagnosis.

306 Mortality is higher among older adults and patients who do not respond to initial treatment.

307 *Pathophysiology*

308 The pathophysiology of the disease is unclear. Many hypothesize that ITP results from the development
309 of IgG autoantibody which targets structural glycoproteins IIb-IIIa situated on the platelet membrane
310 (Stasi & Newland, 2011). This makes platelets prone to the process of phagocytosis by Kupffer cells and
311 splenic macrophages in the liver. However, these autoantibodies have been identified in only 40-60% of
312 patients with ITP (Nazy et al., 2018).

313

314 *Clinical Symptoms*

315 The initial suspicion and severity of ITP can be determined by evaluating the patient's skin and mucous
316 membranes, as well as asking them about their tendency to bruise or bleed minor trauma. As in other
317 primary haemostasis defects, mucocutaneous bleeding and deeper organ bleeding may occur. Clinical
318 signs of ITP include purpura, petechiae, and ecchymosis primarily in the upper and lower limbs.
319 Petechiae may also appear in mucosal membranes, such as the nasal septum, hard palate, or gums, leading
320 to epistaxis and gum bleeds. Spontaneous widespread hematomas can cause the platelet count to drop
321 below 10k μ /L. Although fatal complications are rare, ITP can be implicated in overt gastrointestinal
322 bleeding or intracerebral haemorrhage (Bohn & Steurer, 2018).

323

324 *Treatment*

325 Clinical observation typically begins when the platelet count drops to 30k/ μ L in the absence of active
326 bleeding. Treatment is initiated when active bleeding occurs. Glucocorticoids are considered the first-line
327 treatment and typically involve the administration of Prednisone at a dose of 1 mg/kg PO OD. If
328 glucocorticoid therapy fails, Rituximab at a dose of 375 mg/m² IV once/week for a month is considered
329 the second line of treatment. In cases of refractory ITP, agents such as Romiplostim (1–10 mcg/kg
330 once/week) and Eltrombopag (25–75 mg once/day) are often used (Bohn & Steurer, 2018). While full

331 remission can be achieved in approximately two-thirds of patients by splenectomy, this treatment comes
332 with the risk of encapsulated bacterial infection and thrombosis. If patients do not respond to
333 glucocorticoid treatment or experience severe bleeding, anti-D immunoglobulin (IG) or IVIG may be
334 recommended.

335

336 *Viral Encephalitis*

337 Encephalitis is a condition characterized by inflammation of the brain parenchyma, which can result in
338 neurological dysfunction caused primarily by infection or autoimmunity. Diagnosis of encephalitis is
339 typically made through the identification of inflammation in brain tissue specimens, but since
340 inflammation in such specimens is not always directly indicated, indirect diagnoses must often be made
341 through ancillary non-invasive tests, including cerebrospinal fluid analysis and neuroimaging. It is
342 important to note that many other neurological conditions can lead to encephalopathy without causing any
343 evidence of inflammation in the parenchyma. Encephalitis is generally suspected when symptoms of
344 neurological dysfunction are observed, such as behavioral changes, focal deficits, decreased level of
345 consciousness, papilledema, seizures, and headaches, alongside systemic manifestations such as rash,
346 myalgia, arthralgia, lymphadenopathy, gastrointestinal symptoms, respiratory symptoms, or a history of
347 exposure to risk factors such as animal bites, endemic areas, or exposure to ticks or insects (Costa & Sato,
348 2020).

349

350 *Pathophysiology*

351 It has been suggested that a wide range of organisms can cause encephalitis, including protozoa,
352 spirochetes, viruses, bacteria, fungi, and Rickettsiae. Among these, viruses are the most common cause of
353 encephalitis worldwide; the most commonly implicated of which are cytomegalovirus (CMV), Herpes
354 simplex virus (HSV1 and HSV2), varicella-zoster virus, chikungunya virus, Nipah virus, dengue virus,
355 and enteroviruses (EVs). The pathophysiology of encephalitis can vary depending on the causative agent
356 involved (Jain, Patel & Bhatt, 2014).

357

358

359 ***Clinical Signs***

360 The major clinical signs of encephalitis include altered mental status, characterized by lethargy,
361 decreased, or altered level of consciousness, or personality changes lasting for more than a day with no
362 other alternative cause found; fever greater than 38°C within 72 hours before or after presentation; partial
363 or generalized seizures that are not completely attributable to the patient's previous seizure disorder;
364 recent onset of focal neurologic outcomes; neuroimaging suggestive of brain parenchyma abnormality;
365 abnormalities detected in electroencephalography that are consistent with encephalitis and not attributable
366 to any other cause.

367

368 ***Treatment***

369 The first line of treatment for suspected encephalitis includes correction and supportive treatment for
370 autonomic dysregulation, hepatic and renal dysfunction, and electrolyte disturbances. It is also important
371 to treat non-convulsive status epilepticus and seizures. If the diagnosis is not confirmed within 6 hours of
372 admission, then it is recommended to start treatment with acyclovir at 500 mg/m² TD for children and
373 adolescents and 10 mg/kg TD for adults. Doses should be adjusted if the patient has a previous history of
374 renal impairment (Costa & Sato, 2020).

375

376 ***Thrombotic Thrombocytopenic Purpura (TTP)***

377 TTP is classified as a type of thrombotic microangiopathy (TMA), a diverse set of disorders characterized
378 by microangiopathic hemolytic anemia, thrombocytopenia, and organ dysfunction resulting from
379 disturbed microcirculation. TTP is a rare disorder occurring in approximately 5 individuals per 1 million
380 annually.

381

382 ***Pathophysiology***

383 In current literature, the pathophysiology of TTP is described as a severe deficiency of ADAMTS13,
384 which can be the result of autoantibodies affecting its function, genetic abnormalities (congenital TTP), or

385 dysregulated clearance of ADAMTS13 (autoimmune TTP). Persistent UL-VWF MM (ultra-large VWF
386 multimers) results in the deficiency of ADAMTS13. UL-VWF MM with enhanced platelet aggregation
387 occurs in the presence of stress-causing agents including, but not limited to, infections, pregnancy,
388 surgery, and certain drugs. The aggregation of platelets causes an impedance in the flow of blood in the
389 microcirculation, leading to clinical symptoms and organ damage. Although the central nervous system
390 (CNS) is mainly affected by TTP, it also has an impact on other organs, including the heart and kidneys.
391 In patients with acute TTP, platelets rich in von Willebrand factor with no or low fibrin have been
392 identified in capillaries, small vessels, and large vessels (Lämmle, Hovinga & Alberio, 2005).

393

394 ***Clinical Signs***

395 Clinical signs of thrombotic thrombocytopenic purpura (TTP) and other thrombotic microangiopathies
396 (TMAs) are characterized by disturbances in the microcirculation, consumption thrombocytopenia, and
397 symptoms of red cell fragmentation (such as Coombs-negative hemolysis). Red cell fragmentation can be
398 detected by free serum hemoglobin, elevated LDH, anemia, schistocyte count, reticulocyte count,
399 hemoglobinuria, and reduced haptoglobin levels (Knöbl, 2013). Neurological symptoms resulting from
400 brain hypoperfusion, such as blurry speech, headache, dizziness, amaurosis, epileptic seizures, stroke, or
401 coma, can also occur due to TTP. Kidney involvement can lead to increased oligo- or anuria, serum
402 creatinine, and hemolysis-induced hemoglobinuria. Thrombocytopenia may not always present with
403 purpura and bleeding is rare, but hemolysis can cause anemia and jaundice. Cardiac involvement is a
404 dangerous complication for patients with TTP (Mariotte et al., 2016).

405

406 ***Treatment***

407 Plasma exchange therapy is considered the first-line treatment for TTP and has been shown to improve
408 the survival rate of 80-90% of patients. The therapy involves replacing 1.5 times the patient's plasma
409 volume with donor plasma. The donor plasma used can either be virus-inactivated plasma, fresh frozen
410 single donor plasma, pooled donor plasma, or cryosupernatant. During therapy, the UL-VWF MM,

411 autoantibodies, sludges, and immune complexes that are responsible for TTP are removed. This helps in
412 reducing the severity of symptoms and improving the patient's condition.

413 *Plasma infusion*

414 It's important to note that plasma infusion is not typically considered the first-line treatment for TTP.
415 However, in patients with congenital TTP (a rare genetic form of the disorder), plasma infusion may be
416 used as a treatment to replace the missing enzyme ADAMTS13. In these cases, regular prophylactic
417 plasma infusions may also be necessary to prevent further episodes of the disease. The recommended
418 dose for plasma infusion in TTP can vary depending on the severity of the disease and the patient's
419 individual needs.

420

421 *Immunosuppression*

422 If TTP is autoimmune, then immunosuppression is achieved through corticosteroids such as prednisone 1-
423 2 mg/kg to suppress the formation of other antibodies. In other forms of thrombotic microangiopathies,
424 steroids are administered to reduce stress and enhance endothelial function (Zheng et al., 2020).

425

426 *Hemophagocytic Lymphohistiocytosis (HLH)*

427 HLH is an uncommon but serious immunological syndrome characterized by elevated macrophage
428 activity and cytotoxic lymphocytes, leading to multi-organ dysfunction and cytokine-mediated tissue
429 injury. Several key soluble mediators including IL-18, interleukin (IL)-1b, and Interferon-gamma (IFN- γ)
430 characterize HLH immunopathology. HLH has been classified into two forms: primary/familial form (F-
431 HLH) and reactive/sporadic/secondary form. Familial HLH is conferred by the presence of penetrant
432 genetic variation and mutation which affects lymphocyte survival, cytolytic function, and inflammasome
433 activation. On the other hand, acquired factors such as infection, malignancy, and chronic inflammation
434 constitute the basis for reactive HLH (Grom, Horne & De Benedetti, 2016).

435

436 *Pathophysiology*

437 The underlying mechanism of HLH is yet to be elucidated. HLH is a distinct state of the activated
438 immune system which can be achieved through several pathways depending on the environmental
439 triggers and predispositions of the individual. Note that HLH is primarily driven by the abnormal immune
440 system of an individual as opposed to underlying triggering agents. Moreover, the immune response in
441 HLH, mediated by the activation of cytotoxic T-cells (CD8 β T-cells in particular) differs from the
442 immune response in autoimmune disease as it does not target self-antigen agents. Chronic inflammation
443 and immunosuppression also serve as predisposing factors for HLH. In such conditions, HLH is mostly
444 triggered by viruses, but intracellular pathogens can also serve as triggering agents (Allen & McClain,
445 2015). Genetic mutations leading to HLH are clustered around the genes responsible for proteins
446 implicated in lymphocyte activation and survival as well as cell-mediated cytotoxicity.

447

448 ***Clinical Signs***

449 Early diagnosis of HLH is crucial as patients can rapidly progress to multiorgan failure and death.
450 Patients with HLH typically present with a persistently high fever, as well as other symptoms such as
451 lymphadenopathy, hepatomegaly, splenomegaly, dysfunction of the CNS (including seizures or altered
452 mental status), coagulopathy, and liver dysfunction. In some cases, patients may develop shock (Ramos-
453 Casals et al., 2014). A common feature of HLH is a persistent high fever that does not respond to standard
454 fever-reducing medications. Hepatomegaly is present in both children and adults with HLH, while
455 splenomegaly is common but not present in all cases.

456

457 ***Treatment***

458 The treatment approach for HLH depends on the severity of the disease and the underlying triggering
459 agent, if identified. The primary goal of treatment is to control inflammation, which is the underlying
460 mechanism driving the disease. A multidisciplinary team approach is often necessary to provide
461 comprehensive care for patients with HLH. Supportive care with blood products may be necessary for

462 patients with abnormal blood clotting, and ventilator support may be required for critically ill patients

463 with respiratory failure (Janka & Lehmborg, 2013).

464

465

466 *Postural Orthostatic Tachycardia Syndrome (POTS)*

467 POTS is a clinical syndrome that presents with a variety of symptoms experienced by patients while
468 standing, including palpitations, light-headedness, generalized weakness, tremors, exercise intolerance,
469 blurred vision, and fatigue. A hallmark of POTS is an increase in heart rate of at least 30 bpm (or at least
470 40 bpm in individuals aged 12-19 years) within 10 minutes of moving from a reclining to a standing
471 position. POTS is diagnosed when orthostatic hypotension, defined as a drop in systolic blood pressure of
472 at least 20 mmHg, is absent. Presyncope symptoms are common in patients with POTS; standing heart
473 rate is typically ≥ 120 bpm and higher in the morning than in the evening.

474

475 *Pathophysiology*

476 Assuming an upright posture typically results in blood shifting from the chest to the legs and lower
477 abdomen, and a significant volume of plasma moving from the vasculature to the interstitial space. This
478 plasma shift can reduce venous return and lead to decreased stroke volume, cardiac filling, and arterial
479 pressure. The compensatory sympathetic response, activated by baroreceptor signalling, can increase
480 heart rate and systemic vasoconstriction, which restores cardiac output and venous return. In POTS,
481 however, these physiological regulations are often compromised, resulting in reduced cardiac output, lack
482 of normalization of cardiac volume, reduced venous return, and enhanced heart rate while standing. The
483 underlying pathophysiology of POTS is not fully understood, but multiple factors likely contribute to the
484 disorder, resulting in varied symptoms among individuals. Symptoms of POTS may result from excessive
485 orthostatic shift in plasma volume, hypovolemia, increased sympathetic tone, enhanced blood venous
486 pooling or poor venous return, physical deconditioning, autonomic dysfunction, and immunological
487 factors (Wells et al., 2017).

488

489 *Clinical Signs*

490 Orthostatic symptoms are the most frequent clinical manifestations of POTS, and they can be divided into
491 non-cardiac symptoms (such as light-headedness, headaches/migraines, brain fog, nausea, weakness,

492 tunnel/blurred vision, fatigue, and tremulousness) and cardiac symptoms (such as chest discomfort,
493 exercise intolerance, dyspnoea, and heart palpitations). Light-headedness and presyncope are the most
494 commonly reported symptoms in POTS, although only 30% of patients faint. It is important to note,
495 however, that symptoms of POTS can also be non-orthostatic and general, including problems with
496 sleeping, fatigue, migraines, daytime sleepiness, and hypermobility of joints (Mar & Raj, 2020).

497

498 ***Treatment***

499 The treatment of POTS involves both pharmacological and non-pharmacological approaches. Non-
500 pharmacological treatments, which should be the first line of treatment, include exercise, increased salt
501 and fluid intake, muscle tensing, using compression garments, modifying diet, and discontinuing
502 medications that worsen the symptoms. POTS patients should also avoid stressors such as alcohol
503 consumption, extreme heat, and dehydration.

504

505 Pharmacological treatments for POTS target the underlying cause of the disorder and aim to reduce heart
506 rate, improve peripheral vasoconstriction, and increase intravascular volume. Midodrine and
507 fludrocortisone are the most commonly prescribed medications, but their side effects may not be well-
508 tolerated by some patients.

509

510 *Guillain-Barrè syndrome (GBS)*

511 GBS is a rare, but serious, neurological disorder characterized by flaccid, acute, and neuromuscular
512 paralysis. It was first described over a century ago, and since then, numerous studies have been conducted
513 to investigate its presentation, immune-mediated pathophysiology, prognostic models, and treatment
514 outcomes (Yuki & Hartung, 2012). GBS is typically classified as an "acute inflammatory demyelinating
515 polyradiculopathy" because it affects the spinal cord and peripheral nerves, causing inflammation and
516 damage to the myelin sheath that surrounds and protects nerve fibers. This damage can result in muscle
517 weakness, arflexia, and sensory deficits, among other symptoms.

518 ***Pathophysiology***

519 GBS is considered to be an autoimmune disorder in which the immune system mistakenly attacks the
520 myelin sheath covering nerve fibers in the peripheral nervous system (PNS). This results in inflammation,
521 demyelination, and, in severe cases, axonal degeneration. The attack on the myelin sheath and nerve
522 fibers leads to a breakdown in communication between the nerves and muscles, resulting in the
523 characteristic flaccid paralysis seen in GBS (Leonhard, Ziemann, & Spies, 2021). The exact cause of GBS
524 is not fully understood, but it is believed to be triggered by a preceding infection or vaccination in some
525 cases.

526

527 ***Clinical Signs***

528 GBS is characterized by distal and proximal weakness, which can be flaccid and profound when the
529 patient is hospitalized. As the disease progresses, patients may require intubation due to respiratory
530 muscle weakness. GBS may also present with hyporeflexia and areflexia. Sensory symptoms, which are
531 length-dependent, accompany the areflexia and flaccid weakness. Facial diplegia can also develop as both
532 of the facial cranial nerves may be involved (Fokke et al., 2014).

533

534 ***Treatment***

535 The first-line treatments for GBS are plasma exchange therapy and IVIG. Plasma exchange therapy
536 removes humoral mediators, pathogenic antibodies, and complement proteins, which are often pathogenic
537 agents for GBS (Chevret, Hughes & Annane, 2017). IVIG exerts its therapeutic effects through immune-
538 modulating actions.

539

540 ***Discussion***

541 The objective of the systematic review was to identify and characterize post-COVID-19 infection
542 syndromes. The review identified six syndromes described in the literature, and a qualitative synthesis

543 was conducted to synthesize the literature around their diagnosis and treatment methods. Here, we
544 hypothesise potential mechanisms of how COVID-19 infection may lead to each of these syndromes.
545 Several pathways have been proposed that may lead to thrombocytopenia after COVID-19 infection,
546 including the interaction of platelets with the virus through pathogen recognition receptors,
547 hemophagocytosis caused by cytokine storms, sepsis, immune complexes and autoantibodies against
548 platelets, platelet activation in lung tissue leading to coagulopathy, and microthrombi formation and
549 damaged lung tissue leading to reduced platelet counts from megakaryocytes (Xu, Zhou & Xu, 2020).
550 However, the most common mechanism leading to ITP is thought to be molecular mimicry between
551 platelet glycoproteins and viral components. A study by Zhang et al. (2009) showed that protein
552 sequences are shared between glycoprotein IIIa found on platelets and hepatitis C core-envelope peptides,
553 which can trigger the production of antibodies that can fragment platelets. However, no sequence
554 homology has been identified between platelet components and SARS-CoV-2 infection, so the exact
555 mechanism remains unclear.

556
557 Three major pathways describe the underlying mechanism of SARS-CoV-2 infection causing
558 encephalitis: the blood circulation pathway, direct infection injury, and neuronal pathways. Given that we
559 know the functional receptor for the SARS-CoV-2 virus to be the ACE-2 receptor, which is present on the
560 capillary endothelium, glial cells, and neurons, the blood circulation pathway suggests that these cells are
561 thus potential targets for the virus, which may then enter the CNS through said receptors (Zhao et al.,
562 2020). Another mechanism is the direct entry of the virus through the cribriform plate in the brain. Since
563 the SARS-CoV-2 virus usually replicates in the nasopharyngeal epithelium, it can cause damage to
564 neuronal tissue in the same manner as it does in olfactory nerves (Corona, Rodríguez-Violante &
565 Delgado-García, 2020). Dynein and kinesin proteins in nerves, such as the vagus nerve, may also be
566 responsible for the retrograde and anterograde transportation of the virus in the brain, facilitating insult
567 via neuronal pathways (Zhao et al., 2020).

568

569 Viruses are known to commonly trigger thrombotic microangiopathies, but the exact mechanism leading
570 to TTP from COVID-19 infection is unknown. However, several pathways have been proposed, including
571 a high inflammatory state associated with cytokine storms, direct endothelial injury, or mediation via
572 enhanced procoagulant factors such as von Willebrand factor, fibrinogen, and factor VIII (Panigada et al.,
573 2020). Pascreau et al. (2021) observed 70 COVID-19 patients and determined their antigen levels, plasma
574 VWF activity, and ADAMTS 13 antigen levels. They found a marked increase in VWF levels, which was
575 associated with a decrease in ADAMTS13 levels, a pathognomonic indicator for TTP.

576

577 It has been proposed in the literature that the SARS-CoV-2 virus can cause cytokine storm including
578 HLH, as there are many similarities in the clinical presentation of COVID-19 and HLH (Mehta et al.,
579 2020). Poor outcomes have been observed for patients with SARS-CoV and MERS, which are associated
580 with enhanced levels of proinflammatory cytokines (e.g., IL-1 β) in body tissues, specifically in the lower
581 respiratory tract (He et al., 2006). Increased levels of IL-1 β enhance the production of other
582 proinflammatory cytokines, including IL-6 and TNF- α , which can result in cytokine storm (Nieto-Torres
583 et al., 2014). Therefore, SARS-CoV-2 may trigger secondary HLH in some patients.

584

585 The proposed mechanism for POTS post-COVID-19 infection is the dysregulation of the renin-
586 angiotensin-aldosterone system (RAAS) due to the interaction of the SARS-CoV-2 virus with ACE2
587 receptors. ACE2 receptors are found on the endothelial cells of various organs including the lungs, heart,
588 and kidneys; and we know that the virus binds to these receptors to enter the cell. This interaction can
589 result in the downregulation of ACE2 receptors, which leads to an increase in angiotensin II levels,
590 resulting in vasoconstriction, inflammation, and oxidative stress. This can lead to endothelial dysfunction
591 and microvascular damage, ultimately leading to the development of POTS (Kanjwal et al., 2021).

592

593 It has been proposed in the literature that SARS-CoV-2 causes GBS syndrome in some patients either
594 directly by binding with ACE2 receptors on neuronal tissue and manifesting their neuroinvasive capacity

595 or indirectly through an autoinflammatory mechanism. Molecular mimicry may also play a role in the
596 development of GBS in some COVID-19 patients. Molecular mimicry occurs when the immune system
597 mistakes a viral protein for a self-protein, leading to an autoimmune response against the body's tissues. A
598 study by Toscano et al. (2020) reported that five COVID-19 patients with GBS had antibodies against
599 gangliosides, which are molecules found on nerve cell membranes that can be targeted by the immune
600 system in GBS. The antibodies were found to cross-react with the SARS-CoV-2 spike protein, supporting
601 a potential role of molecular mimicry as the underlying mechanism. However, more research is needed to
602 fully understand the mechanisms underlying GBS in COVID-19.

603

604 **Conclusions**

605 Since the emergence of Coronavirus infectious Disease 2019 (COVID-19) in late December 2019, several
606 vaccines have been made which subsided the pandemic; however post-COVID-19 infection, multiple
607 syndromes have been reported globally. The intention of writing this systemic review is to summarise all
608 the reported cases and hypothesised pathophysiology that might have led to the manifestation of the
609 syndrome. Total of 12 studies were included which met the eligibility criteria where the reported studies
610 were: immune thrombocytopenic purpura (ITP), viral encephalomyelitis, hemophagocytic
611 lymphohistiocytosis, thrombotic thrombocytopenic purpura (TTP), Guillain-Barrè syndrome (GBS) and
612 postural orthostatic tachycardia syndrome (POTS). Furthermore, presenting symptoms and treatment for
613 each respective syndrome were discussed with brief background on coronavirus and its variants to
614 provide a foundation on which to examine the syndromes manifested after COVID-19 infection.

615

616

617

618

619

620

621

622

623 **Declarations**

624

625 *Competing interests*

626 The authors declare that they have no competing interests.

627

628 *Funding*

629 None.

630

631 *Authors' contributions*

632 SA conceptualised the systematic review and prepared the initial draft of the manuscript. AZ
633 supported writing of the draft and oversaw its critical review and editing. *Both SA and AZ
634 contributed equally to this work as co-first-authors. SK, AT, and KT undertook the literature
635 search and helped prepare the manuscript draft. All authors read and approved the final
636 manuscript.

637

638

639

640

641

642

643

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

644

645

646

647

648 **References**

649 Allen, C. E., & McClain, K. L. (2015). Pathophysiology and epidemiology of hemophagocytic
650 lymphohistiocytosis. *Hematology 2014, the American Society of Hematology Education Program*
651 *Book, 2015*(1), 177-182.

652

653 Aromataris, E. and Pearson, A., 2014. The systematic review: an overview. *AJN The American Journal of*
654 *Nursing, 114*(3), pp. 53-58.

655

656 Awadasseid, A., Wu, Y., Tanaka, Y., & Zhang, W. (2021). SARS-CoV-2 variants evolved during the
657 early stage of the pandemic and effects of mutations on adaptation in Wuhan populations. *International*
658 *journal of biological sciences, 17*(1), 97.

659

660 Bohn, J. P., & Steurer, M. (2018). Current and evolving treatment strategies in adult immune
661 thrombocytopenia. *memo-Magazine of European Medical Oncology, 11*(3), 241-246.

662

663 Carod-Artal, F. J. (2020). Neurological complications of coronavirus and COVID-19. *Revista de*
664 *neurologia, 70*(9), 311-322.

665

666 Casalino, L., Gaieb, Z., Goldsmith, J. A., Hjorth, C. K., Dommer, A. C., Harbison, A. M. & Amaro, R. E.
667 (2020). Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein. *ACS central*
668 *science, 6*(10), 1722-1734.

669

670 Centers for Disease Control and Prevention. (2020). Coronavirus Disease 2019 (COVID-
671 19).[Accessed on 30/11/2022] Available from:

672 https://www.cdc.gov/coronavirus/2019ncov/variants/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvariants%2Fabout-variants.html

673 [www.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvariants%2Fabout-variants.html](https://www.cdc.gov/coronavirus/2019-ncov/variants/about-variants.html)

- 674 Challen, R., Brooks-Pollock, E., Read, J. M., Dyson, L., Tsaneva-Atanasova, K., & Danon, L. (2021).
675 Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort
676 study. *BMJ*, 372. doi: 10.1136/bmj.n579
677
- 678 Chen, Y., Liu, Q., & Guo, D. (2020). Emerging coronaviruses: genome structure, replication, and
679 pathogenesis. *Journal of medical virology*, 92(4), 418-423.
680
- 681 Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., ... & Team, N. I. C. (2021). SARS-
682 CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in
683 Maharashtra, India. *Microorganisms*, 9(7), 1542.
684
- 685 Chevret, S., Hughes, R. A., & Annane, D. (2017). Plasma exchange for Guillain-Barré syndrome.
686 Cochrane Database of Systematic Reviews, doi: 10.1002/14651858.CD001798.pub3.
687
- 688 Corona, T., Rodríguez-Violante, M., & Delgado-García, G. (2020). Neurological manifestations in
689 coronavirus disease 2019. *Gaceta médica de México*, 156(4), 313-316.
690
- 691 Costa, B. K. D., & Sato, D. K. (2020). Viral encephalitis: a practical review on diagnostic approach and
692 treatment. *Jornal de Pediatria*, 96, 12-19.
693
- 694 *Coronavirus cases*: Worldometer. (n.d.). <https://www.worldometers.info/coronavirus/>
695
- 696 Dong, N., Yang, X., Ye, L., Chen, K., Chan, E. W. C., Yang, M., & Chen, S. (2020). Genomic and
697 protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus

698 which caused a pneumonia outbreak in Wuhan, China. BioRxiv.
699 <https://doi.org/10.1101/2020.01.20.913368>
700
701 Fehr, A. R., & Perlman, S. (2015). Coronaviruses: an overview of their replication and
702 pathogenesis. *Coronaviruses*, 1-23.
703
704 Fokke, C., van den Berg, B., Drenthen, J., Walgaard, C., van Doorn, P. A., & Jacobs, B. C. (2014).
705 Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. *Brain*, 137(1), 33-43.
706
707 Garland, E. M., Celedonio, J. E., & Raj, S. R. (2015). Postural tachycardia syndrome: beyond orthostatic
708 intolerance. *Current neurology and neuroscience reports*, 15(9), 1-11.
709
710 Grom, A. A., Horne, A., & De Benedetti, F. (2016). Macrophage activation syndrome in the era of
711 biologic therapy. *Nature Reviews Rheumatology*, 12(5), 259-268.
712
713 Guilmot, A., Maldonado Sloopjes, S., Sellimi, A., Bronchain, M., Hanseeuw, B., Belkhir, L. & Van Pesch,
714 V. (2021). Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. *Journal of*
715 *neurology*, 268(3), 751-757.
716
717 He, L., Ding, Y., Zhang, Q., Che, X., He, Y., Shen, H., ... & Jiang, S. (2006). Expression of elevated
718 levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation
719 to the acute lung injury and pathogenesis of SARS. *The Journal of Pathology: A Journal of the*
720 *Pathological Society of Great Britain and Ireland*, 210(3), 288-297.
721 Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (2019).
722 *Cochrane Handbook for Systematic Reviews of Interventions* (2nd ed.). John Wiley & Sons. ISBN: 978-
723 1-119-26361-2 (paperback); 978-1-119-26362-9 (e-book).

724

725 Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (2019).
726 Cochrane Handbook for Systematic Reviews of Interventions (2nd ed.). John Wiley & Sons.

727

728 Imbach, P., & Crowther, M. (2011). Thrombopoietin-receptor agonists for primary immune
729 thrombocytopenia. *New England Journal of Medicine*, 365(8), 734-741.

730

731 Jain, S., Patel, B., & Bhatt, G. C. (2014). Enteroviral encephalitis in children: clinical features,
732 pathophysiology, and treatment advances. *Pathogens and global health*, 108(5), 216-222.

733

734 Janka, G. E., & Lehmborg, K. (2013). Hemophagocytic lymphohistiocytosis: pathogenesis and treatment.
735 *Hematology 2013, the American Society of Hematology Education Program Book*, 2013(1), 605-611.

736

737 Kamble, P., Daulatabad, V., Patil, R., John, N. A., & John, J. (2022). Omicron variant in COVID-19
738 current pandemic: a reason for apprehension. *Hormone Molecular Biology and Clinical Investigation*,
739 44(1), 89-96. doi: 10.1515/hmbci-2022-0010.

740

741 Knöbl, P. (2013). Treatment of thrombotic microangiopathy with a focus on new treatment
742 options. *Hämostaseologie*, 33(02), 149-159.

743

744 Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., ... & Montefiori, D. C.
745 (2020). Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the
746 COVID-19 virus. *Cell*, 182(4), 812-827.

747 Kupferschmidt, K., & Wadman, M. (2021). Delta variant triggers new phase in the pandemic. *Science*
748 372, 1375-1376 doi:10.1126/science.372.6549.1375

749

- 750 Lämmle, B., Hovinga, J. K., & Alberio, L. (2005). Thrombotic thrombocytopenic purpura. *Journal of*
751 *Thrombosis and Haemostasis*, 3(8), 1663-1675.
- 752
- 753 Li, X., Geng, M., Peng, Y., Meng, L., & Lu, S. (2020). Molecular immune pathogenesis and diagnosis of
754 COVID-19. *Journal of pharmaceutical analysis*, 10(2), 102-108.
- 755
- 756 Li, Z., Tomlinson, A. C., Wong, A. H., Zhou, D., Desforges, M., Talbot, P. J., Benlekbir S., Rubinstein
757 J.L., Rini, J. M. (2019). The human coronavirus HCoV-229E S-protein structure and receptor
758 binding. *Elife*, 2019 Oct 25; 8:e51230. doi: 10.7554/eLife.51230
- 759
- 760 Mallapaty, S. (2021). Delta's rise is fuelled by rampant spread from people who feel fine. *Nature*,
761 596(August), 19. doi: 10.1038/d41586-021-02187-1
- 762
- 763 Mar, P. L., & Raj, S. R. (2020). Postural orthostatic tachycardia syndrome: mechanisms and new
764 therapies. *Annual Review of Medicine*, 71(1), 235-248. doi: 10.1146/annurev-med-042718-043351.
- 765
- 766 Mariotte, E., Azoulay, E., Galicier, L., Rondeau, E., Zouiti, F., Boisseau, P., ... & French Reference
767 Center for Thrombotic Microangiopathies. (2016). Epidemiology and pathophysiology of adulthood-onset
768 thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic
769 purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. *The*
770 *Lancet Haematology*, 3(5), e237-e245. doi: 10.1016/S2352-3026(16)00032-4.
- 771
- 772 Mark Vrabel, M.L.S., 2015, September. Preferred reporting items for systematic reviews and meta-
773 analyses. In *Oncology nursing forum* (Vol. 42, No. 5, p. 552). Oncology Nursing Society

774 Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19:
775 consider cytokine storm syndromes and immunosuppression. *Lancet*, 395(10229), 1033-1034. doi:
776 10.1016/S0140-6736(20)30628-0.
777
778 Michel, M. (2009). Immune thrombocytopenic purpura: epidemiology and implications for
779 patients. *European Journal of Haematology Suppl.*, 71: 3-7.
780
781 Mishra, S., Mindermann, S., Sharma, M., Whittaker, C., Mellan, T. A., Wilton, T. & COVID, T. (2021).
782 Changing composition of SARS-CoV-2 lineages and rise of Delta variant in
783 England. *EClinicalMedicine*, 39:101064.
784
785 Morley, V. J., & Turner, P. E. (2017). Dynamics of molecular evolution in RNA virus populations depend
786 on sudden versus gradual environmental change. *Evolution*, 71(4), 872-883.
787
788 Moschcowitz, E. L. I. (1924). Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto
789 undescribed disease. In *Proc NY Pathol Soc* (Vol. 24, No. 1, pp. 21-24).
790
791 Munn, Z., Barker, T. H., Moola, S., Tufanaru, C., Stern, C., McArthur, A., ... & Aromataris, E. (2020).
792 Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. *JBI*
793 *evidence synthesis*, 18(10), 2127-2133.
794
795 Nakagawa, K., Lokugamage, K. G., & Makino, S. (2016). Viral and cellular mRNA translation in
796 coronavirus-infected cells. *Advances in virus research*, 96, 165-192.
797 Nazy, I., Kelton, J. G., Moore, J. C., Clare, R., Horsewood, P., Smith, J. W. & Arnold, D. M. (2018).
798 Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune
799 thrombocytopenia.

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822